HC Wainwright Reaffirms Buy Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $10.00 price objective on the stock.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Invivyd in a research report on Thursday, March 20th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $7.89.

Invivyd Trading Down 0.9 %

IVVD stock opened at $0.61 on Wednesday. The firm has a 50-day moving average price of $1.00 and a 200-day moving average price of $0.86. Invivyd has a 12 month low of $0.35 and a 12 month high of $4.74. The stock has a market capitalization of $73.18 million, a P/E ratio of -0.31 and a beta of 0.09.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.10. The company had revenue of $13.80 million during the quarter, compared to the consensus estimate of $13.57 million. As a group, equities analysts predict that Invivyd will post -1.64 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Terrance Mcguire sold 86,545 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $0.48, for a total value of $41,541.60. Following the transaction, the director now owns 3,170,231 shares in the company, valued at approximately $1,521,710.88. The trade was a 2.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 17.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Invivyd

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Two Sigma Investments LP raised its position in shares of Invivyd by 125.3% in the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock worth $163,000 after acquiring an additional 204,188 shares in the last quarter. Two Sigma Advisers LP grew its stake in Invivyd by 1,276.5% during the fourth quarter. Two Sigma Advisers LP now owns 304,200 shares of the company’s stock worth $135,000 after purchasing an additional 282,100 shares during the period. Mithril II GP LP bought a new stake in Invivyd in the fourth quarter worth approximately $4,981,000. Deutsche Bank AG lifted its stake in Invivyd by 35.2% in the fourth quarter. Deutsche Bank AG now owns 874,406 shares of the company’s stock valued at $385,000 after buying an additional 227,463 shares during the period. Finally, Jane Street Group LLC boosted its holdings in shares of Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock worth $52,000 after buying an additional 87,358 shares in the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.